跳转至内容
Merck
  • Pulmonary edema measured by MRI correlates with late-phase response to allergen challenge.

Pulmonary edema measured by MRI correlates with late-phase response to allergen challenge.

Experimental lung research (2015-04-07)
Rhys L Evans, Kumar K Changani, Sarah Hotee, Kashmira Pindoria, Simon Campbell, Anthony T Nials, William R Ford, Kenneth J Broadley, Emma J Kidd
摘要

Asthma is associated with reversible airway obstruction, leucocyte infiltration, airways hyperresponsiveness (AHR), and airways remodeling. Fluid accumulation causes pulmonary edema contributing to airways obstruction. We examined the temporal relationship between the late asthmatic response (LAR) following allergen challenge of sensitized guinea-pigs and pulmonary edema measured by magnetic resonance imaging (MRI). Ovalbumin (OVA) sensitized guinea-pigs received either a single OVA inhalation (acute) or nine OVA inhalations at 48 h intervals (chronic). Airways obstruction was measured as specific airways conductance (sG(aw)) by whole body plethysmography. AHR to inhaled histamine and bronchoalveolar lavage for leucocyte counts were measured 24 h after a single or the final chronic ovalbumin challenges. MRI was performed at intervals after OVA challenge and high-intensity edemic signals were quantified. Ovalbumin caused early bronchoconstriction, followed at 7 h by an LAR and at 24 h AHR and leucocyte influx. The bright-intensity MRI edema signal, peaking at 7 h, was significantly (P < .05) greater after chronic (9.0 ± 0.7 × 10(3) mm(3)) than acute OVA (7.6 ± 0.2 × 10(3) mm(3)). Dexamethasone treatment before acute OVA abolished the AHR and LAR and significantly reduced eosinophils and the bright-intensity MRI edema from 9.1 ± 1.0 to 6.4 ± 0.3 × 10(3) mm(3). We show a temporal relationship between edema and the LAR and their parallel reduction, along with eosinophils and AHR, by dexamethasone. This suggests a close causative association between pulmonary edema and impaired airways function.

材料
货号
品牌
产品描述

Sigma-Aldrich
地塞米松, powder, BioReagent, suitable for cell culture, ≥97%
Sigma-Aldrich
地塞米松, ≥98% (HPLC), powder
Sigma-Aldrich
氢氧化铝, reagent grade
Sigma-Aldrich
地塞米松, powder, γ-irradiated, BioXtra, suitable for cell culture, ≥80% (HPLC)
Supelco
地塞米松, Pharmaceutical Secondary Standard; Certified Reference Material
USP
地塞米松, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
地塞米松, meets USP testing specifications
Sigma-Aldrich
吡拉明 马来酸盐
Sigma-Aldrich
地塞米松, tested according to Ph. Eur.
地塞米松, European Pharmacopoeia (EP) Reference Standard
地塞米松, European Pharmacopoeia (EP) Reference Standard
地塞米松, European Pharmacopoeia (EP) Reference Standard
Supelco
吡拉明马来酸, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
地塞米松, VETRANAL®, analytical standard
地塞米松, British Pharmacopoeia (BP) Assay Standard
吡拉明 马来酸盐, European Pharmacopoeia (EP) Reference Standard